Products for Research Use Only

MK-8033

CAT: 0804-HY-13299-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13299-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron) ), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) [1][2].
CAS Number
1001917-37-8
UNSPSC
12352005
Target
C-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MK-8033.html
Concentration
10mM
Purity
98.34
Solubility
DMSO : ≥ 46 mg/mL
Smiles
O=S(NCC1=CC=CC=N1)(CC2=CC=C3C(C(C4=CC(C5=CN(N=C5)C)=CN=C4C=C3)=O)=C2)=O
Molecular Formula
C25H21N5O3S
Molecular Weight
471.53
References & Citations
[1]Northrup AB, et al, Discovery of 1-[3- (1-methyl-1H-pyrazol-4-yl) -5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N- (pyridin-2-ylmethyl) methanesulfonamide (MK-8033) : A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. J Med Chem. 2013 Mar 28;56 (6) :2294-310.|[2]Bhardwaj V, et al. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 2012 Aug;7 (8) :1211-7.|[3]Chandrani Chattopadhyay, et al. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014 Feb 13;9 (2) :e83957.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Popular Products